The Immune Response Company
Welcome to a specialist immunology CRO for customised solutions in drug research with translational human data. Explore us and let’s go for a hike!
Immunology CRO specialising in experimental immunology, immune response and tissue damage analysis
Oncology, immuno-oncology and systemic diseases such as cardiovascular, respiratory, metabolic, and autoimmune conditions and infections are areas of therapeutic development that require advanced immunology understanding, immune-based solutions and translational data.
Immundnz is an immunology CRO with customised services and in-depth knowledge in immune mechanisms and protein biology to provide you with the solutions you need to make better decisions in drug discovery and at the non-clinical and pre-clinical stage.
We are scientists who enjoy hiking and research. We go off the beaten track and specialise in designing, developing and experimenting with pre-clinical models (in vitro and ex vivo) to study immune interactions.
Immune Modelling & Experimental Design
We specialise in designing, developing and experimenting with pre- and non-clinical models (in vitro, ex vivo and in vivo) to study immune interactions.
Immune modelling is the design of an experimental model to test the immune response associated with an infection, a metabolite, or a drug. Studies in experimental immunology commonly involve complex immune pathways that cannot be tested by single or standard assays. The designing of the experiment in a model is necessary with the consideration and knowledge of multiple factors in the signalling cascade, the interaction of multiple cells and their immunogenic or tolerogenic response.
Inflammation & Systemic Conditions
Tissue Damage &
Vaccines, Drug Delivery & Transfection
We are ready to support you at any point in your trail in drug research and development
Immundnz, based on years of immological experience, assists you in answering drug-related issues from the outset of your journey. Whatever path you choose, we can assist you in navigating the immunological terrain via experimental design and modelling.
Early-stage drug development and target validation may benefit greatly from experimental design and modelling. Potentially, it may be used to test preliminary theories concerning the relationships between biological pathways and disease pathologies. With so many possible hypotheses to investigate, the experimental design space for in vitro research is large, but the available experimental capacity is not. We can advise you on your next steps.
The target of your compound maybe a specific function of cells and the associated immune response, such as phagocytosis, cytotoxicity, immunosuppression or the inhibition of a specific intracellular signalling, which may be not specific to a therapeutic area. We will help you to choose a route for your study that focuses on this specific function and incorporate the cell types that are necessary for it.
Immundnz develops and adopts cell-based assays in established (cell lines) and primary cells. The mode of action may be specific to a particular type of cell, such as T cells or Th17 cells, or a combination of cell types such as macrophages and cytotoxic T cells. We will help you follow a cell-based route of study according to what is relevant to the compound mechanism.
Therapeutic Area Route
Immunology is involved in a wide range of therapeutic areas such as oncology, infection, systemic diseases, and also neurologic problems. We help you to follow a path that focuses on the therapeutic area and investigate the immune response that is involved in it.
We help you develop a broad spectrum of assays to qualitatively assess your compound in early phase drug development to truly understand your potential drug targets's profile involved in human disease. We help you choose the best route towards first-in-man clinical trials.
Explore Mode of Action More
Understanding your drug's mechanism of action can provide you with information about the safety of the drug and how it eventually affects patients. It can also support in dose selection of a drug and determining which patients are most likely to respond to treatment. By helping you ask the right questions our experimental design and modelling expertise can accelerate your drug development.
Mitigating Obstacles On Your Course
A lack of translatable testing models may restrict insight into how a drug candidate will behave in the human body during the preclinical research stage. Immundnz's assays can assist you in precisely predicting immunogenicity potential by considering e.g., cell quality, culture conditions, and assay readout parameters. Understanding these risk variables may aid in the creation of successful testing techniques for your drug development program, hence boosting the chance of success and shortening the time to market.
Investigating signaling pathways contributing to disease initiation and progression, involved in drug development, provides the opportunity to conduct clinical trials that use these molecular features to select patients, assign treatment, and evaluate treatment outcomes. This may enable for the design of clinical studies with greater effect sizes and lower sample numbers that can be concluded faster.
When developing therapies that modulate the immune response, its complexity can present a challenge. Immundnz provides immunology assays, which use proven assays and primary cell lines to undertake immunological and pharmacological research into the many opportunities and therapeutic targets. Our mission is helping you better understand your drug.
Whatever path you choose, you will face difficulties. Without a doubt, our strength is in assisting you to overcome them via cautious thinking and unrivaled senior immunology experience. We are experimental design and modeling specialists that like developing answers to complicated immunology issues. Every step of the way.
Thank you for entering our website with a question regarding your therapeutic molecule. Whether you're developing a small molecule, mRNA, protein or other product, the first point on our route is discussing your goals and challenges.
Customised Assays for Tailored Solutions
Every drug in development targets a unique site or function for which every problem is unique and requires a solution that is generated through its assessment. We are experienced scientists who will customise an assay or assays to provide a tailored solution with the understanding of the celluar and signalling pathway that is involved. These assays are immunologic, protein-based and bioanalytical based on primary cells and/or cell lines.
Some of our popular assays:
- M1-M2 Polarisation Assays
- Macrophage Phagocytosis (ADCP)
- Cytokine Release Assay (CRA)
- Mixed Lymphocyte Reaction (MLR)
- Dendritic Cell Maturation and Activation
- T Cell Proliferation
- T Cell Differentiation
- Cell Stress & Apoptosis
- Cell Viability & Cytotoxicity
- Immune & Protein-based Assays
Macrophages are important myeloid cells of the immune system that are phagocytic and secrete cytokines that are instrumental in promoting a pro-inflammatory or regulatory immune response and interact with other immune effectors. The M1 (pro-inflammatory) and M2 (regulatory) are the two main macrophage types that are considered important in drug biology studies. Read more.
Phagocytosis is an immunologic mechanism involved in apoptosis, necrosis, infection and tumour conditions mediated by leukocytes like macrophages, DCs, and neutrophils.
One of the types of phagocytosis is antibody-dependent cellular phagocytosis (ADCP). In this case, antibody-opsonised target cells activate phagocytes via Fc-FcR binding, leading to internalisation and degradation of the target cell. This mechanism is valuable in infection and tumour biology and the basis of many antibody-based drugs. Read more.
Cytokines are small proteins that allow cells of the immune system to communicate with each other. When the Immune System produces these cytokines uncontrollably in response to a biopharmaceutical molecule, for instance, or a viral antigen, a cytokine release syndrome or “cytokine storm” is triggered. As a result, high levels of inflammation are created, which can be fatal. Read more.
Mixed Lymphocyte Reaction (MLR) is an in vitro assay in which immune cells from two different donors are co-cultured together to trigger an immune response. MLR can be performed in different ways. In one-way MLR, T cells from one donor are mixed with antigen-presenting cells from another donor. In two-way MLR, two PBMC populations are combined, each containing both T cells and antigen-presenting cells. The activation of T cells within both populations can be measured simultaneously. The advantage of MLR is that no stimulation with a stimulatory compound is required to induce an immune response. T cells and antigen-presenting cells can be analysed by flow cytometry and/or immune-assays for cytokines, activation markers or intracellular protein expression. MLR is often used as to determine the immunomodulatory potential of a compound, especially their ability to potentiate a T cell response. Read more.
Dendritic cells (DCs) are the star antigen-presenting cells (APCs) of myeloid or haematopoietic origin that play a vital role between the innate and adaptive immune systems.
DCs are pivotal in the T-cell-mediated T-helper response to the MHC ClassII-Ag complex and cross-presenting via the MHC class I pathway. They consist of receptors for pathogen and danger-associated molecular patterns, e.g. TLRs. Read more.
An in vitro T cell proliferation assay can be used to determine whether or not T cells are triggered to divide after exposure to a specific antigen of interest, or to assess differences between cell populations in their ability to divide in response to an antigen. We use flow cytometry to assess markers for T cell proliferation. The T cell proliferation assay can be used to assess modulation of the T cell response by (immunomodulatory) compounds. Read more.
Our in-house human T cell assay is adapted to differentiate Th17 cells from TALL-1 cells. On stimulation (e.g. with PMA), these cells produce IL-17 and IL-22, quantified by intracellular flow cytometry or ELISA. This assay can be performed in 96-well plates to test the effect of compounds on Th17 differentiation and activation (e.g. inhibitory effect) and the viability of Th17 cells. The assay can be also be performed with primary T cells. Read more.
Cell apoptosis is also known as programmed cell death, and is a highly regulated process that allows for proper growth and development by destroying unneeded cells and tissues. An apoptosis assay can detect and quantify the cellular events associated with programmed cell death. We can assess apoptosis and cellular stress in a variety of ways, using flow cytometry, Western blot, microscopy or fluorometric. Read more.
Cell viability assays are used to determine if a test molecule has effects on cell proliferation or if it shows cytotoxic effects that lead to cell death. Cell viability assays can also be used to determine optimal growth conditions in cell culture studies. We can assess cell viability in a variety of ways, using flow cytometry, immune assays, microscopy or colorimetry. Read more.
We perform various immunologic and protein-based assays that are needed in your research or drug development. While we provide standard assays our speciality is in developing custom designed assays suited for your product. Read more.
Learn how Immundnz guides immunologic research
To study the role of heat shock proteins in immune-mediated cell death and autoimmunity, we designed a diabetes model consisting of transgenic expression of the target protein. We initiated cell death of islet beta-cells in a controlled dose-dependent manner. The study successfully revealed that the (i) initial beta cell death was responsible for initiating immune-mediated diabetes, and (ii) the immune response was increased by the overexpression of heat shock protein. This study was essential to understand the role of heat shock proteins in immunogenicity following tissue damage.
Let’s go for a hike. Together.
Our experts are ready to set up a route and be on your way to understand which solution or assay as a path will help you to reach from one point to another in your drug research.
We’d be happy to discuss and help you in your research.